Trioar
South Korea · $27.2M raised
- Employees
- 1–10
- Business Model
- B2B
- Website
- trioar.co.kr
- Total Funding
- $27.2M
- Last Round
- $18.0M Series BJul 2025
- Rounds
- 2
About
South Korean biotech company developing next-generation antibody-based therapeutics including ADC and immuno-oncology platform technologies.
Summary
Trioar is a Biotech company based in South Korea. It has raised $27.2M in total across 2 rounds, most recently a $18.0M Series B round in Jul 2025. Investors include Woori Venture Partners and Shinhan Venture Investment.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Jul 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company